Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
— 2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering — — Company’s Robust Cash Position Provides Funds Beyond 2020 to Fuel Pipeline Advancement and Growth — —...
View HTML
Toggle Summary Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after...
View HTML
Toggle Summary Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2019-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of...
View HTML
Toggle Summary Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2019-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present a...
View HTML
Toggle Summary Dicerna Bolsters Leadership Team to Support Continued Growth
— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb....
View HTML
Toggle Summary ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth
— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb....
View HTML
Toggle Summary Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2019-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of...
View HTML
Toggle Summary Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus
— Clinical Proof-of-Concept Data Expected in Second Half of 2019 — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2019-- Dicerna Pharmaceuticals, Inc . (NASDAQ: DRNA), (the “Company”) a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer...
View HTML
Toggle Summary Dicerna Evolves Its Board of Directors to Support Continued Growth
— J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board — — Company Thanks Departing Chairman David Madden and Director Brian Halak — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- Dicerna Pharmaceuticals, Inc....
View HTML
Toggle Summary Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2019-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019 , the Compensation Committee of the Company's Board of Directors...
View HTML